Scott Stallings

Scott Stallings is a seasoned professional with extensive experience in the pharmaceutical and healthcare sectors. Currently serving as Senior Director and Head of Global Marketing for the Metabolic Disorders Franchise at Alexion Pharmaceuticals, Scott has held several significant roles, including Director of the HCP Team Leader for Soliris (aHUS) and Director of Global Marketing for Soliris (Nephrology). Previously, Scott worked at Pfizer as a Senior Manager in Oncology and at MedEquity Capital as an Associate in a healthcare private equity fund. Scott began their career as an Analyst at JP Morgan, focusing on healthcare mergers and acquisitions. Scott holds an MBA from The Wharton School and a BA in Economics from Brigham Young University.